The Motley Fool··Adria CiminoModerna's 70% Rally Fuels Debate: Growth Story or Overheated Biotech?
Moderna stock surges 70% in 2026 on vaccine and cancer therapy pipeline expansion, but $2.8B losses amid $1.9B revenue temper bullish sentiment.
MRNAbiotechoncology